Sound waves could help chemo reach brain tumors

NCT ID NCT07274787

Not yet recruiting Disease control Sponsor: University of Cincinnati Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether a device called NaviFUS, which uses ultrasound and microbubbles to temporarily open the blood-brain barrier, can safely help the drug bevacizumab reach recurrent glioblastoma tumors more effectively. Ten adults whose brain cancer has returned after standard treatments will receive the combined therapy. The main goal is to check safety, with early signs of effectiveness also being tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) combined with the NaviFUS device that uses ultrasound and microbubbles to temporarily open the blood-brain barrier
What this could lead to: If it works, this could point toward a way to deliver more cancer-fighting drugs to brain tumors, potentially improving treatment for recurrent glioblastoma.
What could go wrong: This is a very early pilot study with only 10 people, so results may not apply to everyone. The approach is new and could fail to show benefit or cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBM

Contacts and locations

Show contact details

Study contacts

Contact
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.